Abstract
Aims
To assess the rate of early awareness to the presence of age-related macular degeneration (AMD) and whether it enables early detection of transition to neovascular AMD (NVAMD) as compared with patients whose first presentation to an ophthalmologist is already at the neovascular stage of disease.
Methods
A retrospective analysis of 268 eyes of 268 consecutive patients with newly diagnosed NVAMD that were treated in a tertiary referral centre was performed. Patients were classified into those who were unaware (Group 1), or aware (Group 2), of the fact that they had AMD before diagnosis of NVAMD. Visual acuity, lesion size and composition, and demographics were compared between both groups.
Results
In all, 185 patients (69%) and 83 patients (31%) were classified to Groups 1 and 2, respectively. Patients in Groups 1 and 2 had similar demographic characteristics, presenting visual acuity and lesion size, and lesion compositions. Group 1 patients were more likely to have a positive history for smoking (41 vs26% in Group 2, P=0.03), whereas Group 2 patients were more likely to have positive family history for AMD (20 vs10%, P=0.02).
Conclusions
These data suggest that current screening methods fail to identify the majority of patients with AMD before the development of NVAMD. The findings also demonstrate that in the routine clinical setting, prior awareness of AMD may not facilitate early detection of treatable choroidal neovascularization lesions.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Olsen TW, Feng X, Kasper TJ, Rath PP, Steuer ER . Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology 2004; 111: 250–255.
Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR . Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805–2816.
Bressler NM . Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001; 119: 198–207.
Rosenfeld PJ, Moshfeghi AA, Puliafito CA . Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331–335.
Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ . Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363–372.
Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003; 136: 407–418.
Grey RH, Bird AC, Chisholm IH . Senile disciform macular degeneration: features indicating suitability for photocoagulation. Br J Ophthalmol 1979; 63: 85–89.
Bressler NM . Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract 2002; 15: 142–152.
Preferred practice pattern: age related macular degeneration. American Academy of Ophthalmology: San Francisco, USA, 2003.
A randomized placebo-controlled clinical trial of high-dose supplementation with vitamins C and E beta carotenezinc for age-related macular degeneration vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119: 1417–1436.
Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration other causes: update. Retina 2005; 25: 119–134.
Lee PP, Feldman ZW, Ostermann J, Brown DS, Sloan FA . Longitudinal rates of annual eye examinations of persons with diabetes and chronic eye diseases. Ophthalmology 2003; 110: 1952–1959.
Sloan FA, Brown DS, Carlisle ES, Picone GA, Lee PP . Monitoring visual status: why patients do or do not comply with practice guidelines. Health Serv Res 2004; 39: 1429–1448.
Klein ML, Jorizzo PA, Watzke RC . Growth features of choroidal neovascular membranes in age-related macular degeneration. Ophthalmology 1989; 96: 1416–1419.
Vander JF, Morgan CM, Schatz H . Growth rate of subretinal neovascularization in age-related macular degeneration. Ophthalmology 1989; 96: 1422–1426; discussion 6–9.
Fine SL . Early detection of extrafoveal neovascular membranes by daily central field evaluation. Ophthalmology 1985; 92: 603–609.
Loewenstein A, Malach R, Goldstein M, Leibovitch I, Barak A, Baruch E et al. Replacing the Amsler grid: a new method for monitoring patients with age-related macular degeneration. Ophthalmology 2003; 110: 966–970.
Roy MS . Vision loss without Amsler grid abnormalities in macular subretinal neovascularization. Ophthalmologica 1985; 191: 215–217.
Achard OA, Safran AB, Duret FC, Ragama E . Role of the completion phenomenon in the evaluation of Amsler grid results. Am J Ophthalmol 1995; 120: 322–329.
Zaidi FH, Cheong-Leen R, Gair EJ, Weir R, Sharkawi E, Lee N et al. The Amsler chart is of doubtful value in retinal screening for early laser therapy of subretinal membranes. The West London Survey. Eye 2004; 18: 503–508.
Arden GB, Wolf JE . Colour vision testing as an aid to diagnosis and management of age related maculopathy. Br J Ophthalmol 2004; 88: 1180–1185.
Fink W, Sadun AA . Three-dimensional computer-automated threshold Amsler grid test. J Biomed Opt 2004; 9: 149–153.
Goldstein M, Loewenstein A, Barak A, Pollack A, Bukelman A, Katz H et al. Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age-related macular degeneration. Retina 2005; 25: 296–303.
Acknowledgements
This work was presented in part in the ARVO annual meeting, Fort Lauderdale, FL, USA, 30 April–4 May 2006.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cervantes-Castañeda, R., Banin, E., Hemo, I. et al. Lack of benefit of early awareness to age-related macular degeneration. Eye 22, 777–781 (2008). https://doi.org/10.1038/sj.eye.6702691
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6702691
